2019 IPO

Shockwave Medical Stock

Treatment for Advanced Cardiovascular Disease

Sign up today and learn more about Shockwave Medical Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

Founded

2009

Notable Investors

T. Rowe Price

Headquarters

Fremont CA, US

Total Funding

$133M

About Shockwave Medical Stock

Shockwave Medical is developing the Lithoplasty™ family of balloon dilatation catheters that incorporate tiny lithotripsy electrodes designed to increase the compliance of rigid vascular and valvular lesions prior to low-pressure dilation, thereby limiting injury to healthy tissue and overcoming significant limitations of current revascularization technologies. The technology is built on traditional balloon catheter platforms rendering it inherently familiar and easy to use for cardiologists, interventional radiologists and vascular surgeons alike. In peripheral vessels, Lithoplasty™ could enable more effective angioplasty, less frequent bailout stent usage and enhanced lesion preparation prior to the use of drug eluting balloons (DEB) or bio-absorbable vascular scaffolds (BVS). In coronary vessels it could facilitate stent delivery and enhance vessel preparation prior to stent or BVS placement. Finally, in aortic valves the technology could vastly improve native tissue preparation prior to trans-catheter aortic valve replacement (TAVR) and valvuloplasty for those patients not suitable for TAVR.

Investors

Funding History

January 2014$12.5M
May 2015$40.0M
November 2016$45.0M
October 2017$35.0M

Management

Co-Founder

Todd Brinton

Founder, Senior Advisor

Daniel Hawkins

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo